American Century Companies Inc. Has $20.44 Million Holdings in Emergent BioSolutions Inc. (NYSE:EBS)

American Century Companies Inc. increased its holdings in shares of Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 23.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,137,712 shares of the biopharmaceutical company's stock after acquiring an additional 404,667 shares during the period. American Century Companies Inc. owned approximately 3.95% of Emergent BioSolutions worth $20,437,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of EBS. State Street Corp grew its stake in Emergent BioSolutions by 864.7% in the 3rd quarter. State Street Corp now owns 1,911,327 shares of the biopharmaceutical company's stock valued at $15,960,000 after acquiring an additional 1,713,200 shares during the last quarter. Oak Hill Advisors LP purchased a new stake in shares of Emergent BioSolutions in the third quarter valued at about $9,296,000. Allspring Global Investments Holdings LLC acquired a new stake in shares of Emergent BioSolutions in the fourth quarter valued at approximately $1,831,000. Jacobs Levy Equity Management Inc. purchased a new position in shares of Emergent BioSolutions during the 3rd quarter worth approximately $1,547,000. Finally, Prescott Group Capital Management L.L.C. raised its position in shares of Emergent BioSolutions by 250.0% during the 4th quarter. Prescott Group Capital Management L.L.C. now owns 210,000 shares of the biopharmaceutical company's stock worth $2,008,000 after purchasing an additional 150,000 shares during the last quarter. Hedge funds and other institutional investors own 78.40% of the company's stock.

Insider Buying and Selling

In other Emergent BioSolutions news, Director Neal Franklin Fowler sold 35,000 shares of Emergent BioSolutions stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $5.83, for a total value of $204,050.00. Following the completion of the transaction, the director now directly owns 101,100 shares in the company, valued at $589,413. The trade was a 25.72 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 1.20% of the company's stock.

Remove Ads

Analyst Ratings Changes

A number of equities research analysts have commented on the company. HC Wainwright reiterated a "buy" rating and set a $15.00 target price on shares of Emergent BioSolutions in a report on Tuesday. StockNews.com lowered Emergent BioSolutions from a "buy" rating to a "hold" rating in a research note on Wednesday, March 5th.

Emergent BioSolutions Trading Down 6.5 %

Emergent BioSolutions stock traded down $0.34 during midday trading on Thursday, reaching $4.84. The stock had a trading volume of 1,585,411 shares, compared to its average volume of 2,645,901. The stock's 50-day simple moving average is $7.58 and its 200 day simple moving average is $8.56. Emergent BioSolutions Inc. has a twelve month low of $1.82 and a twelve month high of $15.10. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88. The stock has a market capitalization of $262.72 million, a PE ratio of -1.18 and a beta of 1.80.

Emergent BioSolutions (NYSE:EBS - Get Free Report) last released its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.40. The company had revenue of $194.70 million during the quarter, compared to analyst estimates of $254.67 million. Emergent BioSolutions had a negative net margin of 18.55% and a negative return on equity of 9.91%. During the same quarter in the prior year, the business earned ($0.77) earnings per share. Analysts expect that Emergent BioSolutions Inc. will post -0.63 EPS for the current year.

Emergent BioSolutions declared that its Board of Directors has initiated a share repurchase program on Monday, March 31st that allows the company to repurchase $50.00 million in shares. This repurchase authorization allows the biopharmaceutical company to repurchase up to 19% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company's board of directors believes its stock is undervalued.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.